SCHEMBL7128957

SCHEMBL7128957

Cc1[nH]c(C=O)c(C)c1CC(=O)N1CCC(O)CC1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
LIPE Q05469 1/20 0.33
MAPT P10636 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.31
LMNA P02545 2/20 0.31
POLB P06746 1/20 0.31
MAPK1 P28482 1/20 0.31
CHRM2 P08172 1/20 0.30
CHRM4 P08173 1/20 0.30
CHRM1 P11229 1/20 0.30
CHRM3 P20309 1/20 0.30
NPC1 O15118 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7126930 0.85 LMNA (0.40) ALDH1A1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL7124274 0.84 HTT (0.43) ALDH1A1KDM4EHSD17B10KMT2AMAPT
SCHEMBL7126259 0.80 POLB (0.33) ALDH1A1HPGDKMT2APOLB
SCHEMBL5401530 0.79 MCL1 (0.40) ALDH1A1KDM4EHPGDHSD17B10KMT2A
SCHEMBL6220089 0.74 SPR (0.41) ALDH1A1SMN1; SMN2MAPTLMNANPC1
SCHEMBL7118385 0.74 PDE5A (0.37) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL7118384 0.74 PDE5A (0.37) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL7117397 0.73 OPRK1 (0.43) NPC1
SCHEMBL7117403 0.73 OPRK1 (0.43) NPC1
SCHEMBL5401557 0.73 KDM4E (0.44) ALDH1A1KDM4EKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US disclosed
WO-2002096361-A2 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. (US) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 ALDH1A1 2773/4885KDM4E 931/4885HPGD 2940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.